Thrombin fragment (TP508) decreases myocardial infarction and apoptosis after ischemia reperfusion injury.
BACKGROUND
Myocardial ischemia-reperfusion injury may lead to cardiac dysfunction or death. This study investigates the potential efficacy of a novel thrombin fragment (TP508) on myocardial ischemia-reperfusion injury.


METHODS
Fourteen male Yucatan pigs underwent 60 minutes of mid-left anterior descending coronary artery occlusion followed by 120 minutes of reperfusion. Pigs received either saline vehicle (control, n = 7) or thrombin fragment TP508 (n = 7) as a bolus (0.5 mg/kg) 50 minutes into the ischemic period, followed by continuous intravenous infusion (1.25 mg x kg(-1) x h(-1)) during reperfusion. Myocardial function was monitored throughout the experiments. Monastryl blue/triphenyl tetrazolium chloride staining was utilized to measure the area at risk and infarcted tissue. Apoptosis was assessed by Western blotting and dUTP nick-end labeling (TUNEL) staining. Coronary microvascular reactivity to endothelium-dependent factors (adenosine diphosphate, substance P, A23187) and endothelium-independent factor (sodium nitroprusside) was examined.


RESULTS
Global and regional left ventricular function was not significantly different between groups. Endothelium-dependent coronary microvascular relaxation was greater in the TP508 group and associated with higher endothelial nitric oxide synthase phosphorylation. Both infarct size and TUNEL staining was significantly decreased in the TP508 group compared with the control group (p < 0.05). Expression of the cell survival proteins B-cell lymphoma 2 (2.2-fold, p < 0.05) and heat shock protein-73 (1.6-fold, p < 0.05) was higher in the TP508 group. Expression of the cell-death-signaling proteins poly adenosine diphosphate-ribose polymerase (1.6-fold, p < 0.05), cleaved poly adenosine diphosphate-ribose polymerase (6.4-fold, p < 0.05), and B-cell lymphoma 2/adenovirus E1B 19 kDa-interacting protein 3 (3.8-fold, p < 0.05) was significantly higher in the TP508 group in the ischemic territory.


CONCLUSIONS
This study demonstrates that TP508 decreases infarct size, improves endothelial microvascular function, and induces cell-survival signaling in the setting of ischemia-reperfusion injury. Thus, TP508 may be a useful agent to attenuate myocardial reperfusion injury.
Osipov
Robert M
RM
Department of General Surgery, Cardiothoracic Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Bianchi
Cesario
C
Clements
Richard T
RT
Feng
Jun
J
Liu
Yuhong
Y
Xu
Shu-Hua
SH
Robich
Michael P
MP
Wagstaff
John
J
Sellke
Frank W
FW
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D008297:Male; D009203:Myocardial Infarction / Q000209:etiology* / Q000517:prevention & control*; D015428:Myocardial Reperfusion Injury / Q000150:complications*; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D013552:Swine; D013917:Thrombin
D010446:Peptide Fragments; C412222:rusalatide acetate; D013917:Thrombin